Latanoprost

Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea[1].

Product Specifications

CAS Number

[130209-82-4]

Product Name Alternative

PHXA41

UNSPSC

12352005

Hazard Statement

H301, H361

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Field of Research

Others; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Latanoprost.html

Purity

99.85

Solubility

DMSO : ≥ 100 mg/mL|Ethanol : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C[C@@H]1O

Molecular Formula

C26H40O5

Molecular Weight

432.59

Precautions

H301, H361

References & Citations

[1]Pauly A, et al. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012 Dec 13;53 (13) :8172-80.|[2]Tsai S, et al. The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs. Vet Ophthalmol. 2013 Sep;16 (5) :370-6.|[3]Zheng J, et al. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol. 2011 May;31 (4) :597-604.|[4]Ooi YH, et al. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009 Nov;50 (11) :5259-65.|[5]B'Ann True Gabelt, et al. Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys.